ArticleDiscover nano2025
Histopathological and biochemical profiling of Carfilzomib-loaded Fe-Co MOFs.
Article in Discover nano, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, new medications like proteasome inhibitors (PIs) have significantly improved cancer patients' response rate and overall survival. Carfilzomib (CFZ), a second-generation proteasome inhibitor, has shown promising results in clinical trials for treating multiple myeloma patients. In the current study, a Fe-Co metal-organic framework (MOF) was developed as a drug delivery system for targeted therapy of cancer cells. CFZ-loaded Fe-Co MOFs were synthesized and characterized using DLS, VSM, SEM-EDS, and BET analyses. The in vivo effects of CFZ-loaded Fe-Co MOFs were compared with standard drugs using a male Wistar rat model. Based on the results, DLS revealed a polydisperse size distribution, while VSM showed strong magnetic properties with 20 emu/g saturation magnetization. SEM-EDS confirmed a well-defined crystalline structure with uniform elemental distribution, and BET analysis indicated a mesoporous structure with a surface area of 84.984 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.